42 results
PRER14A
GLSHQ
Gelesis Holdings, Inc.
7 Sep 23
Preliminary revised proxy
4:03pm
through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced … ”). PureTech Health plc’s research and development engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two
PREM14A
GLSHQ
Gelesis Holdings, Inc.
24 Jul 23
Preliminary proxy related to merger
9:47pm
and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders … (the “Founded Entities”). PureTech Health plc’s research and development engine has resulted in the development of 27 therapeutics and therapeutic candidates
8-K
EX-2.1
GLSHQ
Gelesis Holdings, Inc.
13 Jun 23
Entry into a Material Definitive Agreement
7:29am
, strategic alliance, collaboration, co-promotion, commercialization or research or development Contract, in each case, which requires, or would … or other contingent payments based on any research, testing, development, regulatory filings or approval, sale, distribution, commercial manufacture
424B3
cfwsz2xau8f
16 Nov 22
Prospectus supplement
4:51pm
424B3
iw27258 xp4967xb
16 Nov 22
Prospectus supplement
4:48pm
8-K
EX-99.1
prkx93gkl bb
14 Nov 22
Gelesis Reports Third Quarter 2022 Results
8:56am
424B3
z34kvn8
16 Sep 22
Prospectus supplement
11:19am
424B3
tuli50
6 Sep 22
Prospectus supplement
4:53pm
8-K
EX-99.1
m4r538 3lcrjn4bc
15 Aug 22
Gelesis Reports Second Quarter 2022 Results
7:01am
424B3
tdn6j407d
8 Jun 22
Prospectus supplement
4:21pm
8-K
EX-99.1
xn6oqu1qrtoql gjnas
12 May 22
Results of Operations and Financial Condition
4:01pm